Difficulty: Medium
Average Score: 88%
Practice
Correct statements about pamidronate include all of the following, EXCEPT:
Correct answer
B
Rationale
In the context of lifespan pharmacology, understanding the pharmacokinetics and pharmacodynamics of pamidronate is crucial for safe and effective patient care. The correct statement about pamidronate, which is option B, is that the skeletal half-life is 24 hours. This is because pamidronate is a bisphosphonate drug that has a prolonged duration of action in the bone tissue, leading to its extended skeletal half-life.
Option A is incorrect because pamidronate is indeed not available as an oral preparation primarily due to poor bioavailability and the potential for severe gastrointestinal side effects, rather than gastric irritation. Option C is incorrect as fever and lymphocytopenia associated with pamidronate are typically reversible upon discontinuation of the drug. Option D is incorrect because pamidronate is not known to cause esophageal irritation; instead, it can cause irritation to the gastrointestinal tract if not administered properly intravenously.
Educationally, understanding these nuances is vital for healthcare professionals to ensure safe medication administration, monitor for potential adverse effects, and provide appropriate patient education regarding pamidronate therapy. This knowledge also aids in clinical decision-making and promotes optimal patient outcomes when managing conditions like osteoporosis or hypercalcemia where pamidronate may be indicated.
Option A is incorrect because pamidronate is indeed not available as an oral preparation primarily due to poor bioavailability and the potential for severe gastrointestinal side effects, rather than gastric irritation. Option C is incorrect as fever and lymphocytopenia associated with pamidronate are typically reversible upon discontinuation of the drug. Option D is incorrect because pamidronate is not known to cause esophageal irritation; instead, it can cause irritation to the gastrointestinal tract if not administered properly intravenously.
Educationally, understanding these nuances is vital for healthcare professionals to ensure safe medication administration, monitor for potential adverse effects, and provide appropriate patient education regarding pamidronate therapy. This knowledge also aids in clinical decision-making and promotes optimal patient outcomes when managing conditions like osteoporosis or hypercalcemia where pamidronate may be indicated.